Zynex Inc. (OTCMKTS:ZYXI) CFO Purchases $49,494.63 in Stock

Zynex Inc. (OTCMKTS:ZYXI) CFO Daniel J. Moorhead purchased 2,733 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was purchased at an average price of $18.11 per share, for a total transaction of $49,494.63. Following the acquisition, the chief financial officer now owns 19,001 shares of the company’s stock, valued at approximately $344,108.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of ZYXI opened at $19.12 on Friday. The company has a market capitalization of $663.58 million, a price-to-earnings ratio of 86.91 and a beta of 1.05. The stock has a 50 day moving average of $23.36 and a 200 day moving average of $16.05. Zynex Inc. has a 12 month low of $7.51 and a 12 month high of $29.73.

Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $0.09 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.09. The company had revenue of $19.26 million during the quarter, compared to the consensus estimate of $19.12 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. Sell-side analysts anticipate that Zynex Inc. will post 0.28 EPS for the current year.

A number of research analysts have recently weighed in on ZYXI shares. Northland Securities restated a “hold” rating and issued a $22.50 target price on shares of Zynex in a report on Wednesday. Piper Sandler started coverage on Zynex in a report on Monday, July 20th. They issued an “overweight” rating and a $30.00 target price on the stock. HC Wainwright dropped their target price on Zynex from $30.00 to $25.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, B. Riley upgraded Zynex from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Wednesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $23.50.

Institutional investors and hedge funds have recently modified their holdings of the stock. Citigroup Inc. increased its position in Zynex by 310.6% in the fourth quarter. Citigroup Inc. now owns 3,170 shares of the company’s stock worth $25,000 after buying an additional 2,398 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Zynex by 121.9% in the first quarter. BNP Paribas Arbitrage SA now owns 4,866 shares of the company’s stock worth $54,000 after buying an additional 2,673 shares during the last quarter. Winslow Evans & Crocker Inc. purchased a new stake in Zynex in the second quarter worth $107,000. Cubist Systematic Strategies LLC purchased a new position in shares of Zynex in the fourth quarter valued at $111,000. Finally, Federated Hermes Inc. purchased a new position in shares of Zynex in the first quarter valued at $117,000. 0.05% of the stock is owned by institutional investors.

About Zynex

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Featured Story: Backdoor Roth IRA Conversion and Strategy

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.